PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2025

  • ID: 3845313
  • Report
  • Region: Global
  • 424 pages
  • GlobalData
1 of 5
Meningococcal Vaccines Market Set to Approach $1.8 Billion by 2025
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2025

Summary

Neisseria meningitidis is a Gram-negative, encapsulated diplococcal bacterium and is the causative agent for invasive meningococcal disease. Although relatively rare around the globe, invasive meningococcal disease is widely feared because of its high mortality rate even in otherwise healthy individuals. The onset of invasive meningococcal disease typically begins within three to seven days of infection, but can occur as early as one day after infection. If left untreated, meningococcal disease progresses rapidly. Even with appropriate treatment, up to 10% of all cases still result in death within 24 to 48 hours of symptom onset. This rapid onset and progression of the disease emphasizes the need for a prophylactic approach by vaccination.

Pharmaceutical companies have developed vaccines addressing the most urgent medical needs based on clinical efficacy and epidemiology. The resulting vaccines can be divided into three categories, although other and finer segmentations can be made. These three categories include monovalent vaccines targeting serogroup C (MenC vaccines), vaccines protecting against most serogroup B strains (MenB vaccines), and tetravalent vaccines protecting against serogroups A, C, W, and Y (MenACWY vaccines). While the MenB vaccines use recombinant proteins as antigens, all other meningococcal vaccines are based on the polysaccharide capsules of the various serogroups.

Highlights

Key Questions Answered

- Based on interviews with key opinion leaders (KOLs), GlobalData has identified key unmet needs in the meningococcal vaccine marketplace.
- What will be the effect of recent and upcoming changes in national immunization schedules?
- How will the new first-in-class vaccine covering all main serogroups (MenABCWY) be received in the different markets?
- What research and development (R&D) strategies will companies leverage to compete in the future meningococcal vaccine marketplace?
- Which patient population(s) are most likely to be targeted for vaccines against serogroup B and the pentavalent MenABCWY pipeline vaccine?

Key Findings

- GlobalData projects the meningococcal vaccine market in the US, 5EU, Japan, and Brazil to grow from approximately $1.1bn in 2015 to $1.8bn in 2025, at a compound annual growth rate (CAGR) of 5.4%. This growth across the 8MM will primarily be driven by the introduction of additional meningococcal vaccines into the national routine infant and adolescent vaccination schedules in some 5EU countries. Further growth will be the result of the launch of a pentavalent MenABCWY vaccine during the forecast period while the commercial meningococcal vaccine markets in Brazil and Japan will experience a decline at a negative CAGR of 1.8% and 0.9% respectively.
- With most countries in the 8MM using serogroup B vaccines only for individuals at high risk of contracting meningococcal disease, the routine application of these protein-based vaccines is seen as the major unmet need to be addressed in the oncoming years.
- GlobalData anticipates that opportunities will center on the improvement of vaccine long-term efficacy whilst addressing the cost effectiveness concerns voiced by various governmental institutions.

Scope

- Overview of meningococcal disease, including epidemiology, etiology, pathophysiology, regional serogroup distribution, as well current routine meningococcal vaccine recommendations of all 8MM covered.
- Topline meningococcal vaccine market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the meningococcal vaccine market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
- Analysis of the current and future market competition in the global meningococcal vaccine marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global meningococcal vaccine market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the meningococcal vaccine market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
READ MORE
Note: Product cover images may vary from those shown
2 of 5
1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Related Reports

3 Disease Overview

3.1 Introduction

3.2 Etiology and Pathophysiology

3.2.1 Etiology

3.2.2 Pathophysiology

3.3 Symptoms

3.4 Prognosis

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and morbidities

4.3 Global Trends

4.3.1 US

4.3.2 5EU

4.3.3 Japan and Brazil

4.4 Forecast Methodology

4.4.1 Sources Used Tables

4.4.2 Forecast Assumptions and Methods

4.4.3 Sources Not Used

4.5 Epidemiological Forecast for IMD (2015-2025)

4.5.1 All IMD Combined

4.5.2 Laboratory-Confirmed Incident Cases of Serogroup B IMD

4.5.3 Laboratory-Confirmed Incident Cases of Serogroup C IMD

4.5.4 Laboratory-Confirmed Incident Cases of Serogroup Y IMD

4.5.5 Laboratory-Confirmed Incident Cases of Other Serogroup IMD

4.5.6 Distribution of Serogroups

4.5.7 US College Freshmen

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 Limitations of the Analysis

4.6.3 Strengths of the Analysis

5 Disease Management

5.1 Meningococcal Immunization Policy

5.1.1 Routine Immunization Recommendations and Most Frequently Administered Meningococcal Vaccines

5.2 US

5.2.1 Immunization Recommendations

5.2.2 Clinical Practice

5.3 France

5.3.1 Immunization Recommendations

5.3.2 Clinical Practice

5.4 Germany

5.4.1 Immunization Recommendations

5.4.2 Clinical Practice

5.5 Italy

5.5.1 Immunization Recommendations

5.5.2 Clinical Practice

5.6 Spain

5.6.1 Immunization Recommendations

5.6.2 Clinical Practice

5.7 UK

5.7.1 Immunization Recommendations

5.7.2 Clinical Practice

5.8 Japan

5.9 Brazil

5.9.1 Immunization Recommendations

5.9.2 Clinical Practice

6 Competitive Assessment

6.1 Overview

6.2 Product Profiles - MenACWY Vaccines

6.2.1 Menactra

6.2.2 Menveo

6.2.3 Nimenrix

6.3 Product Profiles - MenB Vaccines

6.3.1 Bexsero

6.3.2 Trumenba

6.4 Product Profiles - MenC Vaccines

6.4.1 NeisVac-C

6.4.2 Menjugate

6.4.3 Menitorix

6.5 Other Meningococcal Vaccines

6.5.1 Overview

7 Unmet Needs and Opportunities

7.1 Overview

7.2 A Safe and Effective Universal Meningococcal Vaccine

7.2.1 Unmet Need

7.2.2 Gap Analysis

7.2.3 Opportunity

7.3 Long-Term Protection Against Invasive Meningococcal Disease

7.3.1 Unmet Need

7.3.2 Gap Analysis

7.3.3 Opportunity

7.4 Improvements in Clinical Trial Design

7.4.1 Unmet Need

7.4.2 Gap Analysis

7.4.3 Opportunity

7.5 Improved Vaccine Cost Effectiveness

7.5.1 Unmet Need

7.5.2 Gap Analysis

7.5.3 Opportunity

7.6 A Prenatal Meningococcal Vaccine

7.6.1 Unmet Need

7.6.2 Gap Analysis

7.6.3 Opportunity

7.7 Reducing Vaccination Frequency in Infants

7.7.1 Unmet Need

7.7.2 Gap Analysis

7.7.3 Opportunity

7.8 Enhanced Education and Awareness of the General Population

7.8.1 Unmet Need

7.8.2 Gap Analysis

7.8.3 Opportunity

8 Pipeline Assessment

8.1 Overview

8.2 Clinical Trial Mapping and Future Trends

8.2.1 Clinical Trials by Status

8.2.2 Clinical Trials by Pipeline Vaccine

8.2.3 Future Clinical Trial Design Considerations

8.3 Promising Vaccines in Clinical Development

8.3.1 MenABCWY

8.3.2 Men Quad TT

8.3.3 Brazil MenC Vaccine

8.4 Promising Early-Stage Pipeline Products

9 Current and Future Players

9.1 Overview

9.2 Trends in Corporate Strategy

9.3 Company Profiles

9.3.1 GlaxoSmithKline

9.3.2 Sanofi

9.3.3 Pfizer

10 Market Outlook

10.1 Global Markets

10.1.1 Forecast

10.1.2 Drivers and Barriers - Global Issues

10.2 United States

10.2.1 Forecast

10.2.2 Key Events

10.2.3 Drivers and Barriers

10.3 5EU

10.3.1 5EU

10.3.2 France

10.3.3 Germany

10.3.4 Italy

10.3.5 Spain

10.3.6 UK

10.4 Japan

10.4.1 Forecast

10.4.2 Key Events

10.4.3 Drivers and Barriers

10.5 Brazil

10.5.1 Forecast

10.5.2 Key Events

10.5.3 Drivers and Barriers

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.4 Forecasting Methodology

11.4.1 Vaccine Coverage

11.4.2 Vaccine Approval vs. Routine Schedule Inclusion

11.4.3 Vaccines Included

11.4.4 Key Launch Dates

11.4.5 General Pricing Assumptions

11.4.6 Individual Vaccine Assumptions

11.4.7 Pricing of Pipeline Agents

11.5 Primary Research - KOLs Interviewed for this Report

11.6 Primary Research - Prescriber Survey

11.7 About the Authors

11.7.1 Analyst

11.7.2 Therapy Area Director

11.7.3 Epidemiologist

11.7.4 Managing Epidemiologist

11.7.5 Global Director of Therapy Analysis and Epidemiology

11.7.6 Global Head of Healthcare

11.8 About us

11.9 Disclaimer

1.1 List of Tables

Table 1: Symptoms of Meningococcal Disease

Table 2: Risk Factors and Comorbidities for IMD

Table 3: 8MM, Sources of Laboratory-Confirmed IMD Incidence

Table 4: 8MM, Sources of Laboratory-Confirmed Serogroup B IMD Incidence

Table 5: 8MM, Sources of Laboratory-Confirmed Serogroup C IMD Incidence

Table 6: 8MM, Sources of Laboratory-Confirmed Serogroup Y IMD Incidence

Table 7: 8MM, Sources of Laboratory-Confirmed Other Serogroup IMD Incidence (Includes Serogroups A, W, X, and All Others)

Table 8: 5EU, Japan, and Brazil Sources of Laboratory-Confirmed Serogroup W IMD Incidence

Table 9: Germany, Italy, and Brazil, Sources of Laboratory-Confirmed Serogroup A IMD Incidence

Table 10: College Freshmen Residing in Campus Accommodation

Table 11: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N, Selected Years 2015-2025

Table 12: 8MM and Japan, Age-specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, N (Row %), 2015

Table 13: 7MM, Age-Specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, N (Row %), 2015

Table 14: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N (Row %), 2015

Table 15: 8MM, Laboratory-Confirmed Incident Cases of Serogroup B IMD, All Ages, Both Sexes, N, Selected Years 2015-2025

Table 16: 8MM, Laboratory-Confirmed Incident Cases of Serogroup C IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025

Table 17: 8MM, Laboratory-Confirmed Incident Cases of Serogroup Y IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025

Table 18: 8MM, Laboratory-Confirmed Incident Cases of Other Serogroup IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025

Table 19: College Freshmen in the US, All Ages, Both Sexes, N, Selected Years, 2015-2025

Table 20: National Immunization Recommendation Agencies, 2016

Table 21: National Immunization Recommendations for Meningococcal Vaccines, 2016

Table 22: Most Frequently Administered Meningococcal Vaccines in the Global Markets, 2015

Table 23: Country Profile - US

Table 24: Country Profile - France

Table 25: Country Profile - Germany

Table 26: Country Profile - Italy

Table 27: Country Profile - Spain

Table 28: Country Profile - UK

Table 29: Country Profile - Japan

Table 30: Country Profile - Brazil

Table 31: Leading Vaccines Against Meningococcal Disease, 2015

Table 32: Product Profile - Menactra

Table 33: Efficacy of Menactra for Individuals Receiving Either One- or Two-Dose Regimens

Table 34: Safety of Menactra for Individuals Receiving One Dose of Menactra

Table 35: Menactra SWOT Analysis, 2016

Table 36: Global Sales Forecast ($m) for Menactra, 2015-2025

Table 37: Product Profile - Menveo

Table 38: Efficacy of Menveo

Table 39: Safety of Menveo

Table 40: Menveo SWOT Analysis, 2016

Table 41: Global Sales Forecasts ($m) for Menveo, 2015-2025

Table 42: Product Profile - Nimenrix

Table 43: Efficacy of Nimenrix

Table 44: Safety of Nimenrix

Table 45: Nimenrix SWOT Analysis, 2016

Table 46: Global Sales Forecast ($m) for Nimenrix, 2015-2025

Table 47: Product Profile - Bexsero

Table 48: Efficacy of Bexsero

Table 49: Safety of Bexsero

Table 50: Bexsero SWOT Analysis, 2016

Table 51: Global Sales Forecasts ($m) for Bexsero, 2015-2025

Table 52: Product Profile - Trumenba

Table 53: Efficacy of Trumenba

Table 54: Safety of Trumenba

Table 55: Trumenba SWOT Analysis, 2016

Table 56: Global Sales Forecasts ($m) for Trumenba, 2015-2025

Table 57: Product Profile - NeisVac-C

Table 58: Efficacy of NeisVac-C

Table 59: Safety of NeisVac-C

Table 60: NeisVac-C SWOT Analysis, 2016

Table 61: Global Sales Forecasts ($m) for NeisVac-C, 2015-2025

Table 62: Product Profile - Menjugate

Table 63: Efficacy of Menjugate

Table 64: Safety of Menjugate

Table 65: Menjugate SWOT Analysis, 2016

Table 66: Global Sales Forecasts ($m) for Menjugate, 2015-2025

Table 67: Product Profile - Menitorix

Table 68: Efficacy of Menitorix

Table 69: Safety of Menitorix

Table 70: Menitorix SWOT Analysis, 2016

Table 71: Global Sales Forecasts ($m) for Menitorix, 2015-2025

Table 72: Other Meningococcal Vaccines

Table 73: Unmet Needs and Opportunities for Meningococcal Vaccines

Table 74: Product Profile - MenABCWY

Table 75: Immunogenicity of MenABCWY

Table 76: MenABCWY SWOT Analysis, 2016

Table 77: Global Sales Forecast ($m) for MenABCWY, 2015-2025

Table 78: Product Profile - Men Quad TT

Table 79: Men Quad TT SWOT Analysis, 2016

Table 80: Global Sales Forecasts ($m) for Men Quad TT, 2015-2025

Table 81: Product Profile - Brazil’s MenC

Table 82: Brazil MenC SWOT Analysis, 2016

Table 83: Global Sales Forecast ($m) for Brazil’s MenC, 2015-2025

Table 84: Important Meningococcal Vaccines in Development, 2016

Table 85: Key Companies in the Meningococcal Vaccine Market in the 8MM, 2016

Table 86: GSK’s Meningococcal Vaccines Portfolio Assessment, 2016

Table 87: GSK SWOT Analysis in Meningococcal Vaccines, 2016

Table 88: Sanofi’s Meningococcal Vaccines Portfolio Assessment, 2016

Table 89: Sanofi SWOT Analysis in Meningococcal Vaccines, 2016

Table 90: Pfizer’s Meningococcal Vaccines Portfolio Assessment, 2016

Table 91: Pfizer SWOT Analysis in Meningococcal Vaccines, 2016

Table 92: Global Sales Forecasts ($m) for Meningococcal Vaccines, 2015-2025

Table 93: 8MM Meningococcal Vaccines Market - Drivers and Barriers, 2015-2025

Table 94: US Sales Forecast ($m) for Meningococcal Vaccines, 2015?2025

Table 95: Key Events Impacting Sales for Meningococcal Disease in the US, 2015?2025

Table 96: US Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025

Table 97: 5EU Sales Forecasts ($m) for Meningococcal Vaccines, 2015?2025

Table 98: 5EU Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025

Table 99: France Sales Forecast ($m) for Meningococcal Vaccines, 2015?2025

Table 100: Key Events Impacting Sales for Meningococcal Vaccines in France, 2015?2025

Table 101: France Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025

Table 102: Sales Forecast ($m) for Meningococcal Vaccines in Germany, 2015?2025

Table 103: Key Events Impacting Sales for Meningococcal Disease in Germany, 2015?2025

Table 104: Germany Meningococcal Vaccines market - Drivers and Barriers, 2015?2025

Table 105: Italy Sales Forecasts ($m) for Meningococcal Vaccines, 2015?2025

Table 106: Key Events Impacting Sales for Meningococcal Disease in Italy, 2015?2025

Table 107: Italy Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025

Table 108: Spain Sales Forecast ($m) for Meningococcal Vaccines, 2015?2025

Table 109: Key Events Impacting Sales for Meningococcal Vaccines in Spain, 2015?2025

Table 110: Spain Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025

Table 111: UK Sales Forecast ($m) for Meningococcal Vaccines, 2015?2025

Table 112: Key Events Impacting Sales for Meningococcal Disease in the UK, 2015?2025

Table 113: UK Meningococcal Vaccines market - Drivers and Barriers, 2015?2025

Table 114: Japan Sales Forecasts ($m) for Meningococcal Vaccines, 2015?2025

Table 115: Key Events Impacting Sales for Meningococcal Vaccines in Japan, 2015?2025

Table 116: Japan Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025

Table 117: Brazil Sales Forecasts ($m) for Meningococcal Vaccines, 2015?2025

Table 118: Key Events Impacting Sales for Meningococcal Disease in Brazil, 2015?2025

Table 119: Brazil Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025

Table 120: Key Launch Dates

Table 121: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

1.2 List of Figures

Figure 1: Membrane Structure of N. meningitidis

Figure 2: Genetic Clusters for Polysaccharide Capsules

Figure 3: Laboratory-Confirmed Incidence of IMD in the EU, All Ages, Both Sexes, 2000-2014

Figure 4: 8MM, Laboratory-Confirmed Incident Cases of all IMD, All Ages, Both Sexes, N, Selected Years 2015-2025

Figure 5: 7MM, Age-Specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, 2015

Figure 6: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N, 2015

Figure 7: 8MM, Age-Standardized Laboratory-Confirmed Incidence (Cases per 100,000 Population) of IMD, All Ages, by Sex, 2015

Figure 8: 8MM, Laboratory-Confirmed Incident Cases of Serogroup B IMD, All Ages, Both Sexes, N, Selected Years 2015-2025

Figure 9: 8MM, Laboratory-Confirmed Incident Cases of Serogroup C IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025

Figure 10: 8MM, Laboratory-Confirmed Incident Cases of Serogroup Y IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025

Figure 11: 8MM, Laboratory-Confirmed Incident Cases of Other Serogroup IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025

Figure 12: 8MM, Serogroup Distribution of Laboratory-Confirmed Incident IMD Cases, %, 2015

Figure 13: 8MM, Serogroup Distribution of Laboratory-Confirmed Incident IMD Cases, %, 2025

Figure 14: College Freshmen Living in Campus Accommodation in the US, All Ages, Both Sexes, N, Selected Years, 2015-2025

Figure 15: National Immunization Schedule for Meningococcal Vaccines across the 8MM

Figure 16: Meningococcal Vaccines - Key Clinical Trial Landscape, 2016

Figure 17: Meningococcal Vaccines - Phase II/III Pipeline, 2016

Figure 18: Competitive Assessment of Late-Stage Pipeline Meningococcal Vaccines, 2015-2025

Figure 19: Clinical and Commercial Positioning of MenABCWY

Figure 20: Clinical and Commercial Positioning of Men Quad TT

Figure 21: Clinical and Commercial Positioning of Brazil’s MenC

Figure 22: Global Sales of Branded Vaccines for Meningococcal Disease by Company, 2015-2025

Figure 23: Company Portfolio Gap Analysis in Meningococcal Vaccines, 2015-2025

Figure 24: Annual Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025

Figure 25: Global Sales for Meningococcal Vaccines by Region, 2015 and 2025

Figure 26: US Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025

Figure 27: Sales of Meningococcal Vaccines by Type of Vaccine in the 5EU in 2015 and 2025

Figure 28: France Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025

Figure 29: Germany Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025

Figure 30: Italy Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025

Figure 31: Spain Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025

Figure 32: UK Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025

Figure 33: Japan Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025

Figure 34: Brazil Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
GlaxoSmithKline
Sanofi
Pfizer
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll